Kidney function predicts new-onset cardiorenal events and mortality in primary aldosteronism: approach of the 2021 race-free eGFR equation
Chun-Fu Lai,Yen-Hung Lin,Kuo-How Huang,Jeff S. Chueh,Vin-Cent Wu,Tai-Shuan Lai,Shao-Yu Yang,Kao-Lang Liu,Chin-Chen Chang,Bo-Ching Lee,Shuo-Meng Wang,Po-Chih Lin,Chi-Sheng Hung,Lian-Yu Lin,Shih-Cheng Liao,Ching-Chu Lu,Chieh-Kai Chan,Leay-Kiaw Er,Ya-Hui Hu,Che-Hsiung Wu,Yao-Chou Tsai,Zheng-Wei Chen,Chien-Ting Pan,Che-Wei Liao,Cheng-Hsuan Tsai,Yi-Yao Chang,Chen-Hsun Ho,Wei-Chieh Huang,Ying-Ying Chen,the TAIPAI study group
DOI: https://doi.org/10.1038/s41440-023-01400-0
2023-09-16
Hypertension Research
Abstract:Individuals with primary aldosteronism (PA) exhibit glomerular hyperfiltration, which may conceal underlying kidney damage. This observational cohort study enrolled 760 coronary artery disease-naive patients diagnosed with PA between January 1, 2007 and December 31, 2018 (male, 45%; mean age, 52.3 ± 11.9 years). The baseline estimated glomerular filtration rate (eGFR) was calculated using the 2021 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation, which includes serum creatinine and cystatin C but omits the race variable. During a mean follow-up of 5.8 ± 3.2 years, new-onset composite cardiovascular events (total death, non-fatal myocardial infarction, and coronary revascularization procedure) occurred at a crude incidence rate of 10.9 per 1,000 person-years. Multivariable Cox proportional hazards analysis showed that baseline eGFR was independently associated with composite cardiovascular events (hazard ratio [HR], 0.98 [95% CI, 0.97–0.99]). Penalized splines smoothing in multivariable regression analysis demonstrated that the risk of composite cardiovascular events increased negatively and linearly when patients had a baseline eGFR less than 85 mL/min/1.73 m 2 . Patients with baseline eGFR <85 mL/min/1.73 m 2 were independently associated with higher risks of composite cardiovascular events (HR, 2.39 [95% CI, 1.16–4.93]), all-cause mortality (HR, 4.63 [95% CI, 1.59–13.46]), and adverse kidney events (sub-distribution HR, 5.96 [95% CI, 3.69–9.62], with mortality as a competing risk). Our data support baseline eGFR as a predictor for new-onset adverse cardiorenal events and emphasizes the importance of the early detection of kidney function impairment in hypertensive patients with PA. We also firstly validate the 2021 race-free CKD-EPI eGFR equation in Asian patents with PA.
peripheral vascular disease